Results 161 to 170 of about 19,323 (198)
[Real-world Study of Icotinib in EGFR Mutant Non-small Cell Lung Cancer Based on the Therapeutic Drug Monitoring]. [PDF]
Han S, Mi L, Fang J, Ma X.
europepmc +1 more source
[Ruxolitinib combined with venetoclax and azacitidine in the treatment of refractory T-ALL patients with JAK1, JAK3, and STAT5B gene mutations: a case report and literature review]. [PDF]
Xu PP +8 more
europepmc +1 more source
[PICALM-MLLT10 fusion gene positive with multiple gene mutations in a child with T-lymphoblastic lymphoma/leukemia: a case report]. [PDF]
Sun Y, Jiang J, Sun LR, Yan FY, Wang LZ.
europepmc +1 more source
Small Cell Lung Carcinoma Metastatic to the Ovary: Reports of Two Cases [PDF]
Chengying SUN +3 more
core
[Resistance to thyroid hormone syndrome with developmental disorders in two children]. [PDF]
Liao LY, Li XF, Zhang XX.
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2022
肺癌是全球第六大死因,也是恶性肿瘤的主要死因之一,非小细胞肺癌(non-small cell lung cancer, NSCLC)是其最常见的类型。表皮生长因子受体(epidermal growth factor receptor, EGFR)基因突变是NSCLC的常见突变之一。针对EGFR基因突变的晚期NSCLC患者,使用EGFR-酪氨酸激酶抑制剂(EGFR-tyrosine kinase inhibitors, EGFR-TKIs)如吉非替尼、阿法替尼 ...
J. Huang, Hong Wang
semanticscholar +1 more source
肺癌是全球第六大死因,也是恶性肿瘤的主要死因之一,非小细胞肺癌(non-small cell lung cancer, NSCLC)是其最常见的类型。表皮生长因子受体(epidermal growth factor receptor, EGFR)基因突变是NSCLC的常见突变之一。针对EGFR基因突变的晚期NSCLC患者,使用EGFR-酪氨酸激酶抑制剂(EGFR-tyrosine kinase inhibitors, EGFR-TKIs)如吉非替尼、阿法替尼 ...
J. Huang, Hong Wang
semanticscholar +1 more source
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2021
骨髓增生异常综合征(MDS)是一种起源于造血干细胞 的异质性恶性克隆性疾病,以造血功能衰竭、病态造血、高风 险向急性髓系白血病(AML)转化为特点。约 30%的 MDS 会转化为AML,24%的患者死于白血病转化。MDS主要 突变靶点是与DNA甲基化、染色质修饰、RNA剪接、转录因 子、信号转导、黏连蛋白和DNA修复有关的基因,有些突变 与AML的驱动突变重叠,提示两者可能拥有共同的克隆起 源;另一些突变则在疾病进展时出现,与疾病的最终转归密 切相关。因此,比较MDS和AML基因突变谱的异同,将 ...
婉淑 Wanshu 陈 Chen +2 more
semanticscholar +1 more source
骨髓增生异常综合征(MDS)是一种起源于造血干细胞 的异质性恶性克隆性疾病,以造血功能衰竭、病态造血、高风 险向急性髓系白血病(AML)转化为特点。约 30%的 MDS 会转化为AML,24%的患者死于白血病转化。MDS主要 突变靶点是与DNA甲基化、染色质修饰、RNA剪接、转录因 子、信号转导、黏连蛋白和DNA修复有关的基因,有些突变 与AML的驱动突变重叠,提示两者可能拥有共同的克隆起 源;另一些突变则在疾病进展时出现,与疾病的最终转归密 切相关。因此,比较MDS和AML基因突变谱的异同,将 ...
婉淑 Wanshu 陈 Chen +2 more
semanticscholar +1 more source

